Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study was to determine whether LCQ908 effectively lowers liver fat, as assessed by MRI and to assess its safety and tolerability profile in subjects with non-alcoholic fatty liver disease (NAFLD).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
History of liver steatosis during the preceding 24 months
History of fasting TGs > 200 mg/dL (confirmed at screening).
Liver fat ≥ 10% as determined by the central MRI laboratory.
Subjects on the following medications can be included if these medications are medically necessary, cannot be stopped and the investigator feels their dose will remain stable for the duration of the double-blind treatment period:
Exclusion criteria
Other protocol defined inclusion/exclusion criteria may apply
Primary purpose
Allocation
Interventional model
Masking
52 participants in 3 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal